Since 1997, Oxford University Innovation has been responsible for creating spinout companies based on academic research generated within and owned by the University of Oxford, and has spun out a new company every two months on average.
Over £2.1bn in external investment has been raised by Oxford University Innovation spinouts since 2010, and eleven are currently listed in London and New York.
The creation of new spinout companies, most of which are listed below, also channels millions of pounds back into University research, benefits local economic development and has created many new jobs in the region.
AnDy marries fine-engineering skills with a deep understanding of the fundamental mechanisms, to produce revolutionary machines that will change the shape of the future, taking inspiration from our environment in order to protect it, and capable of performance beyond anything currently found in nature or engineering.
Incorporated in April 2015
Origin: Oxford University, Department of Zoology
The development of cancer drugs that reprogram cancer cells to undergo the body's natural process of cell death.
Incorporated in April 2016
Origin: Oxford University, Pharmacology
Aurox was established to research, develop, manufacture and commercially exploit products in the field of confocal microscopy and automated pathology slide scanners.
Incorporated in July 2006
Origin: Oxford University, Department of Engineering Science
BioAnalab offers a contract testing service to the biopharmaceutical industry for the rapidly growing area of therapeutic monoclonal antibodies, with a longer-term strategy to develop diagnostics to measure levels of monoclonal antibodies and their immune response. In July 2009, BioAnaLab was acquired by Millipore Corp.
Origin: Oxford University, Department of Pathology
Circadian Therapeutics identify and bring to market pharmaceutical and diagnostic platforms for the effective management of physiological and pathological conditions through their ability to modify the body's circadian rhythms.
Incorporated in September 2016
Origin: Oxford University, Ophthalmology
ClinOx offers clients knowledge and expertise in the development, placement, conduct and analysis of early phase oncology clinical trials, with particular emphasis on pharmacokinetic and mechanistic endpoints.
Origin: Oxford University, Nuffield Division of Clinical and Laboratory Sciences